Build high-quality in vitro neurodegenerative disease models from just 2 days.
Ensure confidence in your workflow with high-quality axoCellsTM astrocytes differentiated from human induced pluripotent stem cells (iPSCs) and assay-ready in just 48 hours. Derived from consenting donor cord blood, our astrocytes have been specifically developed for use in powerful in vitro monoculture models, and complex co-culture systems for drug discovery.
With Axol, you can rely on robust, physiologically relevant astrocytes that express the eight key markers of primary human astrocytes, with low expression of Nestin (a marker of neural stem cells) and MAP2 (a neuronal marker). That means robust, physiologically relevant models of Alzheimer’s Disease, Parkinson’s Disease and ALS.
Supporting quality and consistency
Confidently carry out your neural workflow with iPSCs manufactured in our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Join our customer base of top ten biopharma and academic institutions in building robust, physiologically relevant disease models for research and drug discovery.
How to get highly functional axoCells Astrocytes
- You’ll need Astrocytes ax0665 and all reagents*
- Follow the protocol
- 2 days later you will have highly functional astrocytes
*Additional third party components are required. Be sure to check the protocol before you start using the astrocyte kit.
|Donor gender||Donor age||Source||Condition||Product code||Cells/vials|
|Male||Newborn||Cord blood CD34+ cells||Healthy||ax0665||1 million|
Need a quote for this single product or for the whole cell + media + reagent kit? We’re here to help! Click the ‘get a quote’ button or send an email to email@example.com
- Assay ready in 48 hours
- High relevance with expression of the eight key markers of primary human astrocytes
- Ensure confidence with high-quality cells manufactured in our ISO:9001-accredited production facility under rigorous quality control procedures
- Used by leading organisations for robust mono- and co-culture disease models and for drug discovery
Our axoCellsTM astrocytes have been specifically developed for use in monoculture and complex co-culture systems for in vitro disease modeling and drug discovery.
We have a community of top ten biopharma and research institutes that use our astrocytes to build powerful in vitro models, investigating neurodegenerative disorders (Alzheimer’s, Parkinson’s and ALS) and drug screening.
A fully validated protocol for monoculture of astrocytes is available. In addition, single media protocols, enabling co- and tri-culture of our cortical excitatory neurons with inhibitory interneurons and astrocytes provide convenient and fast solutions to better model human diseases in vitro.
We maintain or exceed industry-level quality with our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience.
All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Licenses & Consent
Axol has obtained all relevant licenses for reprogramming donor samples into iPSCs and differentiating these into astrocytes for commercial use.
Patient samples used to create these cells have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Kumar, M.; Nguyen, N.T.P.; Milanese, M.; Bonanno, G. Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders. Biomolecules 2022, 12, 344. https://doi.org/10.3390/biom12030344
Barak, M., Fedorova, V., Pospisilova, V. et al. Human iPSC-Derived Neural Models for Studying Alzheimer’s Disease: from Neural Stem Cells to Cerebral Organoids. Stem Cell Rev and Rep 18, 792–820 (2022). https://doi.org/10.1007/s12015-021-10254-3